News

Video

Revolutionizing Prostate Cancer Care: 2023’s Transformative Breakthroughs

Author(s):

Rana R. McKay, MD,Tanya B. Dorff, MD

Expert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
View More
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity
View More
Related Content
Evan Y. Yu, MD
April 18th 2025

Investigational and Established Biomarkers Guide Ongoing CRPC Therapy Developments

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Evan Y. Yu, MD
April 16th 2025

Targeted Therapies Both Refine and Raise Questions About CRPC Treatment Decision-Making

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Image Credit:© Sebastian Kaulitzki – stock.adobe.com
April 14th 2025

Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology, Memorial Sloan Kettering Cancer Center
April 11th 2025

PSMAfore Data Drive Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC